<DOC>
	<DOCNO>NCT00005030</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase I trial compare effectiveness different dos SCH 66336 surgery treating patient colorectal cancer metastasize liver .</brief_summary>
	<brief_title>SCH 66336 Before Surgery Treating Patients With Colorectal Cancer That Has Metastasized Liver</brief_title>
	<detailed_description>OBJECTIVES : I . Determine biologic activity safety preoperative SCH 66336 patient colorectal carcinoma metastatic liver . OUTLINE : This randomize , multicenter study . Patients randomize one four dos preoperative SCH 66336 ( treatment , 100 mg , 200 mg , 300 mg ) . Patients receive oral SCH 66336 twice daily 7-14 day prior exploratory laparotomy and/or resection hepatic metastasis . Patients randomized treatment may undergo surgery time within 15 day randomization . Other patient undergo surgery day 8-15 . PROJECTED ACCRUAL : A total 40 patient ( 10 per arm ) accrue study within 10 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer radiologically document liver metastasis Meet institutional criterion exploratory laparotomy and/or resection hepatic metastasis No central nervous system ( CNS ) metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : Not specify Hematopoietic : white blood count ( WBC ) great 3,000/mm3 Platelet count great 150,000/mm3 Hemoglobin least 10 g/dL ( transfusion and/or epoetin alfa allow stable without treatment least 1 week ) Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT great 5 time ULN Renal : Creatinine le 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No poor medical risk nonmalignant systemic disease No active uncontrolled infection No intractable vomiting ( e.g. , grade 2 high despite antiemetic ) medical condition could preclude take oral medication gastrointestinal absorption No AIDS relate illness HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent immunotherapy Chemotherapy : No 2 prior chemotherapy regimens systemic disease At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy , include oral contraceptive No concurrent systemic corticosteroid Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy great 30 % bone marrow Whole pelvic radiation alone exclusionary No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery Other : At least 4 week since prior investigational therapy recover No prior farnesyl protein transferase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>